Cargando…
JAK inhibitors and infections risk: focus on herpes zoster
Currently, there is a growing interest in Janus kinase (JAK) intracellular signalling since targeted inhibitors against these pathways are proving effective in the treatment of a range of immune-mediated diseases, such as rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA), inflammatory...
Autores principales: | Sunzini, Flavia, McInnes, Iain, Siebert, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328488/ https://www.ncbi.nlm.nih.gov/pubmed/32655703 http://dx.doi.org/10.1177/1759720X20936059 |
Ejemplares similares
-
Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
por: Evangelatos, Gerasimos, et al.
Publicado: (2020) -
Factors associated with sepsis risk in immune-mediated inflammatory
diseases receiving tumor necrosis factor inhibitors: a nationwide
study
por: Chao, Wen-Cheng, et al.
Publicado: (2020) -
Hidradenitis suppurativa: infection, autoimmunity, or both?
por: Constantinou, Costas A, et al.
Publicado: (2019) -
Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations
por: Koutsianas, Christos, et al.
Publicado: (2020) -
Mortality risk prediction in lupus patients complicated with invasive
infection in the emergency department: LUPHAS score
por: Wu, Wanlong, et al.
Publicado: (2019)